Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis.
Potential For Cell-mediated Immune Responses In Mouse Models Of Pelizaeus-Merzbacher Disease.
Dextromethorphan/Quinidine for the treatment of pseudobulbar affect.
There is still a role for the blink reflex in the diagnosis and follow-up of multiple sclerosis.
BCG vaccine for clinically isolated syndrome and MS: Infections and protective immunity.
Chronic Acquired Demyelinating Polyneuropathy following Renal Transplantation.
Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.
Human interferon regulatory factor 5 homologous epitopes of Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis induce a specific humoral and cellular immune response in multiple sclerosis patients.
An updated role of microRNA-124 in central nervous system disorders: a review.
FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.
Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats.
Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis).
Neuroinflammation: no rose by any other name.
[New therapeutic options in multiple sclerosis].
Clinical and MRI phenotype of children with MOG antibodies.
Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event.
Recurrent Guillain-Barré syndrome presenting stereotypic manifestations, positive antiganglioside antibodies, and rapid recovery.
["Time is brain" in relapsing remitting multiple sclerosis : Current treatment concepts in immunotherapy].
Relationship between gait initiation and disability in individuals affected by multiple sclerosis.
Cerebral adenosine A1 receptors are upregulated in rodent encephalitis.
Functional electrical stimulation as a component of activity-based restorative therapy may preserve function in persons with multiple sclerosis.
Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation.
The common marmoset as an indispensable animal model for immunotherapy development in multiple sclerosis.
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.
Pages
« first
‹ previous
…
601
602
603
604
605
606
607
608
609
…
next ›
last »